What we have learned from urinary bladder cancer models

Abstract

Urinary bladder cancer (UBC) is a heterogeneous disease with highly variable clinical outcomes and responses to chemotherapy. Despite some advances in the molecular understanding of UBC, this knowledge still has not been translated to the clinic in terms of improvements in the prognosis and treatment of patients. Suitable urinary bladder tumor models representative of the human disease in terms of histology and behavior are needed to study factors involved in tumor initiation, progression and metastasis. Further, accurate model systems would facilitate identification of new therapeutic targets and predictive markers that could lead to optimization of existing therapies and development of new ones. Many established cancer cell lines derived from human urinary bladder tumors representing different grades and stages have been used as experimental models for UBC study. These cell lines reflect some of the genetic and morphologic alterations observed in human urothelial carcinoma and serve as simplified models to study the behavior of cancer cells in vitro. However, their translational potential is limited due to the artificial conditions, in which the cells are maintained, grown and tested. Animal models offer a more complex and realistic model for the establishment, development, and progression of tumors as well as to evaluate new therapeutic approaches. Over the years, the authors' group has worked with several UBC cell lines, established and characterized chemically induced UBC models, and patient-derived xenografts models. In this study, the authors will provide a summary of the UBC models developed by their group, analyze their translational potential and weaknesses, and define areas that remain to be explored.

Keywords

Animal models / cell lines / tumor behavior / urothelial bladder cancer / xenografts

References

[1] Witjes JA,Cowan NC,Gakis G,Ribal MJ,Sherif A.European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines..Eur Urol2014;65:778-92

[2] Sievert KD,Nagele U,Bedke J,Hennenlotter J,Stenzl A.Economic aspects of bladder cancer: what are the benefits and costs?.World J Urol2009;27:295-300

[3] Netto GJ.Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?.Nat Rev Urol2012;9:41-51

[4] Goebell PJ.Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium..Urol Oncol Semin Orig Investig2010;28:409-28

[5] Burger M,Dalbagni G,Herr H,Kassouf W,La Vecchia C,Lotan Y.Epidemiology and risk factors of urothelial bladder cancer..Eur Urol2013;63:234-41

[6] Druckrey H,Ivankovic S,Mennel HD.Selective induction of bladder cancer in rats by Dibutyl- and N-Butyl-N-butanol (4)-nitrosamine..Z Krebsforsch1964;66:280-90

[7] Soloway MS.Single and combination chemotherapy for primary murine bladder cancer..Cancer1975;36:333-40

[8] Toyoshima K,Hiasa Y,Makiura S.Tissue culture of urinary bladder tumor induced in a rat by N-Butyl-N-(-4-Hydroxybutyl) nitrosamine: establishment of cell line, nara bladder tumor..J Natl Cancer Inst1971;47:979-85

[9] Xiao Z,Brown KM,Halls SB,Moore RB.Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model..Br J Cancer1999;81:638-46 PMCID:PMC2362887

[10] Chan ES,Smith AK,Thomas AA,Larchian WA.Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model..J Urol2009;182:2926-31

[11] Palmeira C,Lameiras C,Silva VM,Santos L.Biological similarities between murine chemical-induced and natural human bladder carcinogenesis..Oncol Lett2010;1:373-7 PMCID:PMC3436375

[12] Oliveira PA,De La Cruz P LF.Experimental bladder carcinogenesis-rodent models..ExpOncol2006;28:2-11

[13] Oliveira PA,Colaço A,Lopes C.DNA content analysis, expression of Ki-67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and Bacillus Calmette-Gue′rin..Anticancer Res2006;26:2995-3004

[14] Dyrskjøt L,Thykjaer T,Jensen JL,Ørntoft TF.Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification..Cancer Res2004;64:4040-8

[15] Williams PD,Theodorescu D.Molecular credentialing of rodent bladder carcinogenesis models..Neoplasia2008;10:838-46 PMCID:PMC2481571

[16] Fichtner I,Gill J,Elbe B,Bibby M.Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas..Eur J Cancer2004;40:298-307

[17] Rubio-Viqueira B.Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients..Clin Pharmacol Ther2009;85:217-21

[18] Dong X,English JC,Yee J,Murray N,Ng RT,Lam WL,Ling V,Wang Y.Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy..Clin Cancer Res2010;16:1442-51

[19] Hidalgo M,Rajeshkumar NV,De Oliveira E,Strawn S,Martell J.A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer..Mol Cancer Ther2011;10:1311-6 PMCID:PMC4629061

[20] Bernardo C,Amaro T,Lopes P,Gärtner F,Ferreira JA.Patient-derived Sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study..Anticancer Res2014;34:735-44

[21] Ferreira JA,Lima L,Silva M,Severino PF,Almeida A,Vitorino R,Oliveira MJ,Dall'Olio F,Santos LL.Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours..Mol Oncol2013;7:719-31 PMCID:PMC5528473

[22] Hoffman RM.Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts..Nat Rev Cancer2015;15:451-2

[23] Yang L.Tumor-host immune interactions and dendritic cell dysfunction..Adv Cancer Res2004;92:13-27

[24] Jäger W,Hayashi T,Awrey S,Anderson S,Haegert A,Erho N,Fazli L,Collins C,Black PC.Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies..Oncotarget2015;6:21522-32 PMCID:PMC4673283

[25] Cutz JC,Bayani J,Xue H,English J,LeRiche J,Squire JA,Lam S.Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes..Clin Cancer Res2006;12:4043-54

[26] Lee CH,Sutcliffe M,Gout PW,Miller DM,Wang YZ.Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models..Gynecol Oncol2005;96:48-55

[27] Pan C,Tepper CG,Davis RR,Ghosh PM,Airhart S,Gandara DR,de Vere White RW.Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy..PLoS One2015;10:e0134346

[28] Park B,Choi YL,Lim JE,Jeon SS,Choi HY.Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue..Cancer Sci2013;104:1-8

[29] Monks A,Skehan P,Paull K,Hose C,Cronise P.Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines..J Natl Cancer Inst1991;83:757-66

[30] Barretina J,Stransky N,Margolin AA,Wilson CJ,Kryukov GV,Reddy A,Murray L,Monahan JE,Meltzer J,Jané-Valbuena J,Thibault J,Raman P,Engels IH,Yu GK,Aspesi PJr,Jagtap K,Wang L,Palescandolo E,Mahan S,Onofrio RC,MacConaill L,Reich M,Mesirov JP,Getz G,Chan V,Weber BL,Warmuth M,Harris JL,Golub TR,Sellers WR,Garraway LA.The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity..Nature2012;483:603-7 PMCID:PMC3320027

[31] Pinto-Leite R,Melo J,Margolin AA,Wilson CJ,Kryukov GV,Reddy A,Murray L,Monahan JE,Meltzer J,Jané-Valbuena J,Thibault J,Raman P,Engels IH,Yu GK,Aspesi PJr,Jagtap K,Wang L,Palescandolo E,Mahan S,Onofrio RC,MacConaill L,Reich M,Mesirov JP,Getz G,Chan V,Weber BL,Warmuth M,Harris JL,Golub TR,Sellers WR,Garraway LA.Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer..Tumour Biol2014;35:4599-617

[32] Ching CB.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway..Lab Invest2010;90:1406-14

[33] Netto GJ.Emerging critical role of molecular testing in diagnostic genitourinary pathology..Arch Pathol Lab Med2012;136:372-90 PMCID:PMC3449141

[34] Pal SK.Differentiating mTOR inhibitors in renal cell carcinoma..Cancer Treat Rev2013;39:709-19 PMCID:PMC4957946

[35] Ciuffreda L,Incani UC.The mTOR pathway: a new target in cancer therapy..Curr Cancer Drug Targets2010;10:484-95

[36] Vasconcelos-Nóbrega C,Arantes-Rodrigues R,Brochado P,Palmeira C,Guedes-Teixeira CI,Palomino LF,Santos L.In vivo and in vitro effects of RAD001 on bladder cancer..Urol Oncol2013;31:1212-21

[37] Pinto-Leite R,Ribeiro E,Santos L.Effect of sirolimus on urinary bladder cancer T24 cell line..J Exp Clin Cancer Res2009;28:3 PMCID:PMC2628648

[38] Neshat MS,Tran C,Thomas G,Frost P,Wu H.Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR..Proc Natl Acad Sci U S A2001;98:10314-9 PMCID:PMC56958

[39] Seront E,Bouzin C,Machiels JP.PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation..Br J Cancer2013;109:1586-92 PMCID:PMC3777009

[40] Pinto-Leite R,Palmeira C,Lopes C,Costa C,Oliveira P.Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer..Biomed Pharmacother2013;67:116-21

[41] Pinto-Leite R,Palmeira C,Cardoso ML,Santos L.Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines..J Toxicol Environ Heal Part A2012;75:788-99

[42] Pinto-Leite R,Ferreira R,Colaço A,Oliveira P.Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines..Urol Oncol Semin Orig Investig2014;32:41.e11-22

[43] Pinto-Leite R,Ferreira R,Oliveira PA.Treatment of muscle invasive urinary bladders tumors: a potential role of the mTOR inhibitors..Biomed Aging Pathol2014;4:169-78

[44] Chan E,Heston W.Mouse orthotopic models for bladder cancer research..BJU Int2009;104:1286-91

[45] Jager W,Janssen C,Awrey S,So AI,Fazli L,Thüroff JW,Black PC.Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach..PLoS One2013;8:e59536

[46] Black PC,Brown GA,Metwalli AR,McConkey DJ,Dinney CP.Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis..BJU Int2010;106:1799-804

[47] Hadaschik BA,Sea JC,Fazli L,Gleave ME.A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging..BJU Int2007;100:1377-84

[48] Voskoglou-Nomikos T,Seymour L.Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models..Clin Cancer Res2003;9:4227-39

[49] Alunad 1 Sansom OJ Leung HY.Exploring molecular genetics of bladder cancer: lessons learned from mouse models..Dis Model Mech2012;5:323-32 PMCID:PMC3339826

[50] Pilon-Thomas S,Vohra N.Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma..J Imrmmol2010;184:3442-9

[51] Fu CL,Herbert DR.A novel mouse model of Schistosoma haematobium egg-induced immunopathology..PLoS Pathog2012;8:el002605